Tyrosine kinase receptors

Merus Announces Financial Results for the First Quarter and Provides Business Update

Retrieved on: 
Thursday, May 6, 2021

Both posters present preclinical data demonstrating that the Dock & Block\xc2\xae activity of Zeno can potently inhibit NRG1 (and NRG1 fusion) signaling through HER3:HER2 and tumorigenesis.

Key Points: 
  • Both posters present preclinical data demonstrating that the Dock & Block\xc2\xae activity of Zeno can potently inhibit NRG1 (and NRG1 fusion) signaling through HER3:HER2 and tumorigenesis.
  • MCLA-129 is a Biclonics\xc2\xae, which binds to EGFR and c-MET and is being investigated for the treatment of solid tumors.
  • Dr. Geuijen has over two decades of experience in discovering and developing antibodies as medicines for clinical evaluation.
  • Merus received an upfront cash payment of $40 million, as well as an equity investment by Lilly of $20 million in Merus common shares.

GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to Enable More Targeted Treatment for Metastatic Breast Cancer Patients

Retrieved on: 
Thursday, May 6, 2021

b'GE Healthcare today announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare.

Key Points: 
  • b'GE Healthcare today announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare.
  • Cerianna has been commercially available in the U.S. since December 2020 and today is accessible to approximately 25 percent of the relevant patient population.
  • "\nCurrently, when treating metastatic breast cancer patients, oncologists base clinical decisions on biopsy results which only represent the sampled area of the tumor.
  • CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR).\n'

AmMax Bio to Present at the BofA Securities 2021 Virtual Healthcare Conference

Retrieved on: 
Thursday, April 29, 2021

b'REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (\xe2\x80\x9cAmMax\xe2\x80\x9d), a private clinical-stage biopharmaceutical company focused on developing novel treatments with AMB-05X, its proprietary anti-CSF1R monoclonal antibody platform, today announced that it will present at the BofA Securities 2021 Virtual Healthcare Conference.

Key Points: 
  • b'REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (\xe2\x80\x9cAmMax\xe2\x80\x9d), a private clinical-stage biopharmaceutical company focused on developing novel treatments with AMB-05X, its proprietary anti-CSF1R monoclonal antibody platform, today announced that it will present at the BofA Securities 2021 Virtual Healthcare Conference.
  • A long-acting AMB-05X with strong anti-fibrotic activity will reduce patient treatment burden and is expected to limit vision loss from macular fibrosis.
  • Overactivation of the CSF1/IL-34 \xe2\x80\x93 CSF1R axis substantially contributes to the inflammation and fibrosis inherent in many diseases.
  • Thus, the potent inhibition of CSF1R activity by AMB-05X represents a novel and powerful means of therapeutic intervention via its dual action.\n'

Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for Neovascular Age-Related Macular Degeneration

Retrieved on: 
Thursday, April 29, 2021

As the world\'s first bispecific fusion protein targeting VEGF and complement, IBI302 can simultaneously inhibit the proliferation of VEGF-mediated signaling pathway and reduce the inflammatory response mediated by complement activation.

Key Points: 
  • As the world\'s first bispecific fusion protein targeting VEGF and complement, IBI302 can simultaneously inhibit the proliferation of VEGF-mediated signaling pathway and reduce the inflammatory response mediated by complement activation.
  • The overall safety profile is similar to that of marketed single-target anti-VEGF drugs.
  • IBI302 was designed to provide more targeted treatment and interventions to the cause of nAMD by adding additional targets.
  • The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.

Black Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Clinical Oncology

Retrieved on: 
Wednesday, April 28, 2021

BDTX-189 is designed as a MasterKey inhibitor targeting a family of previously undrugged and functionally similar oncogenic mutations in a tumor-agnostic manner.

Key Points: 
  • BDTX-189 is designed as a MasterKey inhibitor targeting a family of previously undrugged and functionally similar oncogenic mutations in a tumor-agnostic manner.
  • The ErbB receptors are a group of receptor tyrosine kinases involved in key cellular functions, including cell growth and survival.
  • Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.
  • Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com .\n'

Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, April 27, 2021

Additional information about Takeda\xe2\x80\x99s EAP is available here .\nMobocertinib is an investigational, first-in-class, oral tyrosine kinase inhibitor (TKI) specifically designed to selectively target epidermal growth factor receptor (EGFR) Exon20 insertion mutations.

Key Points: 
  • Additional information about Takeda\xe2\x80\x99s EAP is available here .\nMobocertinib is an investigational, first-in-class, oral tyrosine kinase inhibitor (TKI) specifically designed to selectively target epidermal growth factor receptor (EGFR) Exon20 insertion mutations.
  • In 2019, the U.S. FDA granted mobocertinib Orphan Drug Designation for the treatment of lung cancer with HER2 mutations or EGFR mutations including Exon20 insertion mutations.
  • In April 2020, mobocertinib received Breakthrough Therapy Designation from the FDA for patients with EGFR Exon20 insertion+ metastatic non-small cell lung cancer (mNSCLC) whose disease has progressed on or after platinum-based chemotherapy.
  • In this press release, \xe2\x80\x9cTakeda\xe2\x80\x9d is sometimes used for convenience where references are made to Takeda and its subsidiaries in general.

Lantern Pharma Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget

Retrieved on: 
Monday, April 26, 2021

The manuscript is titled \' The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations\' .

Key Points: 
  • The manuscript is titled \' The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations\' .
  • Existing targeted therapies, such as EGFR or ALK inhibitors, only work in specific, genetically defined patient subsets.
  • "\nThis publication in Oncotarget highlights LP-184\'s nanomolar in vitro potency in primary and metastatic NSCLC models.
  • Lantern Pharma has developed a genomic signature that is believed to predict response in tumors that will be responsive to LP-184.

Worldwide Anaplastic Lymphoma Kinase ALK Inhibitors Industry to 2026 - Featuring Astellas Pharma, AstraZeneca ad Pfizer Among Others

Retrieved on: 
Thursday, April 22, 2021

b'DUBLIN, April 22, 2021 /PRNewswire/ -- The "Global Anaplastic Lymphoma Kinase ALK Inhibitors Market, Drug Sales, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global anaplastic lymphoma kinase inhibitor market is going to witness high growth during the forecast period which is mainly attributed to the rise in prevalence of anaplastic lymphoma kinase positive cancers and high research and development activities in this sector.

Key Points: 
  • b'DUBLIN, April 22, 2021 /PRNewswire/ -- The "Global Anaplastic Lymphoma Kinase ALK Inhibitors Market, Drug Sales, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global anaplastic lymphoma kinase inhibitor market is going to witness high growth during the forecast period which is mainly attributed to the rise in prevalence of anaplastic lymphoma kinase positive cancers and high research and development activities in this sector.
  • The characterization of anaplastic lymphoma kinase (ALK) gene and their role in the development and progression of ALK positive cancer has transformed the cancer therapeutics market.
  • The global anaplastic lymphoma kinase inhibitor market is going to witness high growth rate and is expected to double in next 5 years.
  • In addition to this, several emerging ALK inhibitors along with their clinical trials are also provided in the report.\n'

Acute Myeloid Leukemia (AML): Utilizing Single-Cell Multi-Omics to Uncover its Evolution and Resistance Mechanisms, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, April 21, 2021

b'TORONTO, April 21, 2021 /PRNewswire-PRWeb/ --Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy characterized by the overproduction of abnormal myeloblasts.

Key Points: 
  • b'TORONTO, April 21, 2021 /PRNewswire-PRWeb/ --Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy characterized by the overproduction of abnormal myeloblasts.
  • For patients with FLT3 mutated AML, the FLT3 inhibitors (FLT3i), gilteritinib and quizartinib, can improve patient outcomes.\nHowever, the development of secondary resistance to these drugs remains a major challenge.
  • The acquisition of new mutations and the emergence of new subclones during the course of therapy can drive relapse.
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.\nSydney Perelmutter, Xtalks, +1 (416) 977-6555 x 352, [email protected]\n'

Global Anaplastic Lymphoma Kinase ALK Inhibitors Market (2021 to 2026) - Drug Sales, Price & Clinical Trials Insights - ResearchAndMarkets.com

Retrieved on: 
Monday, April 19, 2021

The characterization of anaplastic lymphoma kinase (ALK) gene and their role in the development and progression of ALK positive cancer has transformed the cancer therapeutics market.

Key Points: 
  • The characterization of anaplastic lymphoma kinase (ALK) gene and their role in the development and progression of ALK positive cancer has transformed the cancer therapeutics market.
  • The advent of these drugs in the market has overcome the limitations of conventional therapies such as chemotherapy and radiotherapy.
  • Apart from this, several clinical trials are ongoing to evaluate the efficacy of these drugs in combination with other chemotherapeutic drugs and immune checkpoint inhibitors.
  • The combinational therapy will increase the efficacy of the drug which can better combat the complexity of the cancer.\nDespite several advantages of anaplastic lymphoma kinase inhibitors in the management of cancer, there are several factors which restrain the growth of the market.